Patient: Page 3
-
Win McNamee/Staff via Getty Images
Despite AbbVie’s Botox prowess, underdog Galderma has leveraged soft skills to succeed in aesthetics
Galderma may not have the biggest name in aesthetics, but as the sector grows past pandemic lows, the company is relying on its people to build a loyal customer base.
By Michael Gibney • Aug. 11, 2022 -
Stock via Getty Images
4 ways to nail the launch of your cell therapy
A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.
By Meagan Parrish • Aug. 10, 2022 -
Mario Tama via Getty Images
The ‘alarming’ spread of Monkeypox — by the numbers
With vaccine and treatment supplies constrained, the virus is becoming ‘less predictable.’
By Meagan Parrish • Aug. 8, 2022 -
MJ_Prototype via Getty Images
Generic subscription services like Mark Cuban’s promise cheaper drugs — but will it work?
Companies like Cost Plus Drugs and DiRx can bring generics directly to consumers at a fraction of the price, but whether it’s enough to fix the inflated U.S. healthcare system is yet to be seen.
By Michael Gibney • Aug. 4, 2022 -
Lisa Maree Williams via Getty Images
Q&ALupus discovery lends clues to the fight against long COVID
So far, pharma has yet to provide an answer for long COVID. But award-winning lupus research by Yale professor Akiko Iwasaki could help lead the way.
By Kelly Bilodeau • July 27, 2022 -
iStock via Getty Images
Democrats think they've found a balance between drug innovation and pricing negotiation
A look at Congress’ push to pass drug pricing reform and why the latest attempt could actually succeed.
By Karissa Waddick • July 26, 2022 -
Stock via Getty Images
The earlier the better: New consortium leverages infant screening to accelerate treatment
Inozyme Pharma has joined a genomic sequencing program developing a novel rapid test for 388 genetic diseases.
By Kim Ribbink • July 25, 2022 -
Chris Hondros / Staff via Getty Images
Q&ABehind Pfizer's new quest to target a 'transformation' in pharma
A combined venture with Roivant — called Priovant Therapeutics — is looking to be a forerunner in the burgeoning autoimmune disease market.
By Kelly Bilodeau • July 25, 2022 -
Maddie Meyer / Staff via Getty Images
Moderna's next vax target? A little-known cause of birth defects
How the mRNA-based biotech is developing the first-ever prophylactic for a devastating virus.
By Karissa Waddick • July 21, 2022 -
Permission granted by John LaMattina
Pfizer's former R&D head takes on drug pricing misconceptions in new book
John LaMattina has something to say about the industry — and he hopes patients are listening.
By Meagan Parrish • July 19, 2022 -
NanoStockk/istockphoto.com
Sponsored by OPEN HealthHow digital health is changing the relationship between patients and health providers
The pandemic has forced the pharmaceutical industry to look at digital in a new way - and it’s driving better health outcomes
July 18, 2022 -
FG Trade via Getty Images
ProfileThe power of the underdog: A rare disease nonprofit working to help patients win against the odds
Elizabeth Izard Apelles is finding innovative ways to champion rare disease patients through an emerging platform from Honeycomb Health.
By Alexandra Pecci • July 13, 2022 -
iStock via Getty Images
Pharma companies take a fresh approach to inclusion in new DTC ads
AstraZeneca and Amgen are emphasizing diversity and authenticity in campaigns for lupus and severe asthma therapies.
By Karissa Waddick • July 5, 2022 -
iStock via Getty Images
With abortion access restricted across the U.S., a new diagnostic aims to eliminate birth control's pain points
The hormonal and genetic test developed by Adyn is designed to predict and prevent adverse birth control side effects.
By Karissa Waddick • June 28, 2022 -
Stock via Getty Images
The oncology market is surging despite a decline in routine screenings
A new report from IQVIA reveals the current challenges — and promise — in cancer drug R&D.
By Kelly Bilodeau • June 28, 2022 -
Permission granted by Dan Vahdat.
Q&A'Nobel Prize of pharma' helps put Huma's digital health platform on the global map
The company’s CEO explains how its Prix Galien award-winning app bridges patient care, treatment support and clinical research.
By Kim Ribbink • June 23, 2022 -
Karissa Waddick/PharmaVoice
#DIA2022: Building 'guardrails' in the FDA's accelerated approval program
Regulatory experts weigh in on ways to enhance the controversial drug approval approach.
By Karissa Waddick • June 21, 2022 -
Valiantsin Suprunovich via Getty Images
The public health sleuth
In her decades-long career, Mary Pittman, CEO of the Public Health Institute, has seen — and helped solve — one public health mystery after another.
By Alexandra Pecci • June 21, 2022 -
Stock via Getty Images
Q&A // Biotech SpotlightBiotech spotlight: Karuna Therapeutics' mission to rejuvenate the field of neuroscience
An effective treatment for psychiatric disorders such as schizophrenia might require a holistic approach to avoid serious side effects, says CEO Steve Paul.
By Kim Ribbink • June 16, 2022 -
ChiccoDodiFC via Getty Images
A patient-funded ALS drug offers hope where few treatments exist
Eledon Pharmaceuticals’ grassroots-backed drug recently entered clinical trials.
By Kelly Bilodeau • June 15, 2022 -
Stock via Getty Images
Q&AA combo of precision meds and diagnostics could disrupt mental healthcare
HMNC Brain Health, a clinical-stage company, is leveraging cutting-edge tech to offer a new approach to mental health challenges.
By Kelly Bilodeau • June 8, 2022 -
Stock via Getty Images
ProfileAfter losing her daughter to a rare disease, Sharon King is looking to rewrite the playbook of drug development
The communications pro is lending her community-building, storytelling expertise to the Bespoke Gene Therapy Consortium.
By Alexandra Pecci • June 7, 2022 -
Jonathan Ross via Getty Images
Pharma giants take on Appalachian cancer rates in newest screening initiative
AstraZeneca and Bristol Myers Squibb are teaming up with the nonprofit Association of Community Cancer Centers to increase lung cancer screening in rural Appalachia for the long haul.
By Karissa Waddick • June 7, 2022 -
iStock via Getty Images
Aduhelm's Medicare woes leave questions about lofty premiums
A single drug’s effect on the premiums that Medicare beneficiaries pay is raising questions about how these levels are set and what factors play a part.
By Kelly Bilodeau • June 2, 2022 -
AndreyPopov via Getty Images
Pharmas can be 'more than medicine' by focusing on preventative care
Why pharma companies are changing their tack to become more than the products they sell.
By Michael Gibney • May 24, 2022
Previous
